Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Titel:
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Auteur:
Harbeck, Nadia Huang, Chiun-Sheng Hurvitz, Sara Yeh, Dah-Cherng Shao, Zhimin Im, Seock-Ah Jung, Kyung Hae Shen, Kunwei Ro, Jungsil Jassem, Jacek Zhang, Qingyuan Im, Young-Hyuck Wojtukiewicz, Marek Sun, Qiang Chen, Shin-Cheh Goeldner, Rainer-Georg Uttenreuther-Fischer, Martina Xu, Binghe Piccart-Gebhart, Martine